New Study Questions FDA’s Assessment of Moderna COVID Vaccine for Males Aged 18-25
Are the Risks Worth It?
A recent analysis has reinforced concerns about the safety of the Moderna COVID-19 vaccine (mRNA-1273) for males aged 18-25. While the FDA previously concluded that the benefits of vaccination outweighed the risks, this new study suggests that the risks, particularly related to myocarditis and pericarditis, may be more significant than previously acknowledged.
Revisiting the FDA’s Assessment
The FDA’s original assessment focused on males aged 18-64, but researchers led by Paul S. Bourdon specifically examined the implications for the younger 18-25 age group. Their findings indicate that the risks of myocarditis and pericarditis may exceed the benefits of preventing COVID-related hospitalizations for this demographic.
Key Findings
The researchers used updated data and expanded the FDA’s analytical framework to include:
- Protection from Prior Infection: Considering immunity gained from previous COVID infections.
- Age Classification: Clarifying hospitalization rates among younger individuals.
- Incidental Hospitalizations: Accounting for patients who test positive for COVID while being treated for unrelated conditions.
The analysis found that the FDA’s benefit-risk ratio of 43.33 was overly optimistic, with the new study yielding a ratio of just 0.67. This suggests that vaccination could lead to more hospitalizations from heart issues than it prevents from COVID for young males.
Implications for Public Health
These findings raise serious questions about the safety of the vaccine for younger males and call for an urgent reassessment by the FDA, CDC, Health Canada, and the Public Health Agency of Canada (PHAC). The study suggests that mRNA-1273 vaccination could result in 16% to 63% more hospitalizations from vaccine-attributable myocarditis/pericarditis compared to COVID hospitalizations prevented over a five-month period.
Conclusion
With numerous studies already highlighting the safety concerns surrounding COVID vaccines, it’s crucial for health officials to carefully consider the risks versus benefits, particularly for younger populations. This latest analysis emphasizes the need for continued research and vigilance in monitoring vaccine safety.
For more details, read the study: A Reanalysis of the FDA’s Benefit-Risk Assessment of Moderna’s mRNA-1273 COVID Vaccine.
Source: TrialSite News, October 18, 2024.
************************************************************************************************************************************